SQ Innovation Secures Series B Funding Following FDA Approval of Subcutaneous Furosemide for Heart Failure
核心洞察
SQ Innovation AG (搜索) successfully closed its Series B financing round led by new board member Marco van der Poel to support the commercial launch of Lasix ONYU.
The FDA approved Lasix ONYU (furosemide injection) 80 mg/2.67 mL for subcutaneous use on October 7, 2025, marking a significant milestone for heart failure (搜索) treatment.
The company appointed two distinguished executives to its board, including former GICC Holdings (搜索) CEO Marco van der Poel and former Birkenstock CFO Erik Massmann.
SQ Innovation AG (搜索) has successfully closed its Series B financing round and strengthened its leadership team following the FDA approval of its innovative heart failure (搜索) treatment, positioning the Swiss life-science company for a major U.S. commercial launch.
The company announced on October 8, 2025, that it has secured Series B funding led by Marco van der Poel, former Chief Executive Officer of GICC Holdings (搜索), Inc./Reaxis Inc., who also joined the company's Board of Directors. The financing provides the necessary capital to support the U.S. commercial launch of Lasix ONYU (furosemide injection) 80 mg/2.67 mL for subcutaneous use, which received FDA approval on October 7, 2025.
Leadership Expansion Strengthens Commercial Strategy
SQ Innovation has appointed two distinguished executives to its Board of Directors as part of its preparation for the U.S. market entry. Alongside van der Poel, the company welcomed Erik Massmann, former Chief Financial Officer of Birkenstock Group (搜索) B.V. & Co. KG, to its board.
These appointments complement the existing board structure, which includes Kevin Murphy, formerly SVP Payer Relations and Managed Care at Aetna CVS Health (搜索), who joined in November 2024. The board is completed by company co-founders Erwin Conradi, who serves as Chairman of the Board, and Pieter Muntendam, MD, who holds the positions of CEO of SQ Innovation AG (搜索) and President of SQ Innovation, Inc.
Novel Subcutaneous Formulation Addresses Heart Failure Treatment Gap
Lasix ONYU represents a significant advancement in heart failure (搜索) treatment delivery, offering a subcutaneous formulation of furosemide, a well-established diuretic medication. The 80 mg/2.67 mL injection is specifically designed for subcutaneous administration, potentially providing patients and healthcare providers with a more convenient treatment option for managing worsening heart failure.
SQ Innovation AG (搜索) describes itself as a life-science company pioneering innovative solutions for the treatment of worsening heart failure (搜索), indicating the company's focused approach to addressing this critical medical condition. The FDA approval of Lasix ONYU marks a pivotal moment for the company's mission to improve treatment options for heart failure patients.
Strategic Positioning for Market Entry
The successful Series B financing, combined with the recent FDA approval, positions SQ Innovation for its anticipated U.S. commercial launch. The timing of the funding round, led by an experienced executive who simultaneously joined the board, demonstrates strategic alignment between the company's financial backing and leadership expertise.
The company has established dedicated resources for stakeholders seeking additional information, including separate websites for corporate information and product-specific details about Lasix ONYU, indicating a comprehensive approach to its market entry strategy.